42464-80-2

Basic information

• Product Name: N-(quinolin-5-yl)acetamide
• Synonyms: acetamide, N-5-quinolinyl-
• CAS NO: 42464-80-2
• Molecular Formula: C₁₁H₁₀N₂O
• Molecular Weight: 186.2099
• Mol File: 42464-80-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 430.9°C at 760 mmHg
• Flash Point: 214.4°C
• Density: 1.242g/cm³
• Vapor Pressure: 1.25E-07mmHg at 25°C
• Refractive Index: 1.677
• CAS DataBase Reference: N-(quinolin-5-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(quinolin-5-yl)acetamide(42464-80-2)
• EPA Substance Registry System: N-(quinolin-5-yl)acetamide(42464-80-2)

Safety Data

• Hazardous Substances Data: 42464-80-2(Hazardous Substances Data)

Upstream product

• 580-19-8 quinolin-7-ylamine 
• 611-34-7 5-Aminoquinoline 
• 108-24-7 acetic anhydride 
• 607-34-1 5-nitroquinoline 
• 91-22-5 quinoline 

Downstream Products

• 185510-52-5 5-(N-acetylamino)-5,6,7,8-tetrahydroquinoline 
• 298182-09-9 N-(5,6,7,8-tetrahydroquinolin-7-yl)acetamide 
• 573758-03-9 5-amino-quinoline-8-carbonitrile 

Relevant articles and documents

An expedient synthesis of novel 2-substituted thiazolo[4,5-f]isoquinolines/ quinolines and benzo[1,2-d:4,3-d']bisthiazoles and their potential as inhibitors of COX-1 and COX-2

An efficient, general synthesis of 2-substituted thiazolo[4,5-f] isoquinolines, thiazolo[4,5-f]-quinolines and benzo[1,2-d:4,3-d']bisthiazoles has been accomplished from 5-nitroisoquinoline/quinoline and 6-nitrobenzothiazole, respectively, and all the products have been thoroughly identified spectroscopically (IR, 1H and 13C NMR, LR/HR EI/FAB/ESI-MS). The synthesis of thiazolo[4,5-f]isoquinolines constitutes the first synthesis of this class of heteroarenes. Eighteen compounds, covering all three types, were screened for inhibition of COX-1 and COX-2, and some of them showed moderate activities. ARKAT-USA, Inc.

Chemokine receptor binding heterocyclic compounds

This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y═H; R1to R7may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6alkyl; R8is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH2)n″group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C1-6alkyl group, (3) a C0-6alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C0-6alkylamino or C3-7cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.